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0.781–0.994. Factor scores were compared across self-re-
ported degree of impact. For discriminate validity, the
staff placed each consumer into one of 4 quartiles to de-
scribe their perception of the consumer’s ability to func-
tion in each factor area. Consumer factor scores then
were compared to staff-reported functional levels. RE-
SULTS: For all factors, consumer factor scores progres-
sively lowered as consumers felt the condition had more
negative impact on their lives (P  0.001). For all factors
but medication effects, consumer factor scores improved
with improving staff-perceived assessment of consumer
functionality (P  0.001). Consumer scores from the
lowest to the highest assigned quartile had average scores
of 42.7%, 49.3%, 54.7%, and 60.0%, respectively. 92%
of consumers considered the survey useful, 92% of staff
considered the survey valuable for monitoring consumer
progress. CONCLUSION: We have established concur-
rent and discriminatory validity for the SOAP-51 which
can be used as an outcomes measure in patient monitor-
ing and management, and health policy decision making. 
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OBJECTIVES: One of the most disconcerting symptoms
associated with Parkinson’s disease (PD) and essential
tremor (ET) is disabling tremor. Treatment options for
this problem include low-risk pharmacologic therapy,
with generally poor effectiveness and unfavorable side ef-
fects, or higher risk surgical interventions such as thalam-
otomy. We describe the health-related quality of life
(HRQL) of patients with disabling tremor and assess
their preferences for treatment outcomes in the form of
utilities. METHODS: The MOS Short-Form 36 (SF-36)
was used to characterize the patients’ HRQL. Standard
gamble (SG) and visual analog scale (VAS) approaches
were used to determine patient preferences among 12 PD
and 9 ET health state descriptions. Data on patients’ ap-
praisal of their current health state were also correlated
with indicators of functional disability (Schwab & En-
gland) and HRQL (SF-36) using Spearman’s Rho (	). RE-
SULTS: Sixty-two patients, 31 tremor-dominant PD and
31 ET, participated in the study. Mean age of the sample
was 65 years; 65% (n  40) were male. PD and ET pa-
tients assigned the lowest mean SG health utilities to the
health state description for a thalamotomy with partial
or no improvement and permanent cognitive impairment
(mean  standard deviation: PD: 0.56  0.25 and ET:
0.49  0.27). The highest mean utilities were assigned to
thalamotomy with full improvement and no permanent
impairment (PD: 0.95  0.02 and ET: 0.90  0.18). Cur-
rent health state SG utilities were highly correlated with
indicators of disability and HRQL (	  0.35 to 0.64).
CONCLUSIONS: Results suggest these patients are rela-
tively risk averse. Subjects preferred disability associated
with tremor over disability associated with cognitive or
speech impairment that can occur with thalamotomy.
The greatest patient-to-patient variability was found in
the least desirable health states.
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OBJECTIVES: To compare clinical characteristics, treat-
ment choices, sociodemographic features, baseline and
follow-up HRQOL of African American (AA) and Cau-
casian men with prostate cancer. METHODS: 1178 newly
diagnosed patients (82% Caucasian, 12% AA) from the
CaPSURE database (a national database of patients with
prostate cancer) were studied. Baseline cancer stage,
grade, PSA, comorbidity, treatment selection and base-
line and post-treatment HRQOL were assessed using the
SF-36 and the UCLA Prostate Cancer Index. The impact
of ethnicity on these outcomes was determined. RE-
SULTS: Significant differences (P  0.001) were noted
between ethnic groups. AA men were younger, less edu-
cated and had lower income than Caucasians. AA men
were more likely to have high-stage (i.e. N or M)
(10% vs. 1%) disease and higher pretreatment PSA (12.7
ng/ml vs. 7.5 ng/ml). AA men were more commonly
treated with androgen deprivation (37% vs. 26%). Clini-
cally and statistically significant (
  7, P  0.001) dif-
ferences in baseline HRQOL were noted in AA men who
had poorer: General Health, Physical Function, Bodily
Pain, Role Emotional Function, Sexual Bother, Self Es-
teem, and Health Distress. While both groups improve in
HRQOL 18 months after treatment, AA had worse out-
come in several domains: Bodily Pain, Self Esteem, Health
Distress, Physical Function, General Health, Role Emo-
tional, Urine Function and Bother, Bowel Function and
Bother. Differences were statistically and clinically signif-
icant. CONCLUSIONS: Significant differences exist in
baseline clinical presentation, sociodemographics, and
general HRQOL between AA and Caucasian men with
prostate cancer. These differences remain after treatment.
Interventions, which might reduce these differences, need
to be developed.
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